支持进医保！两部门印发《支持创新药高质量发展的若干措施》，创新药ETF国泰（517110）涨超1.4%，机构表示看好支付端修复

Group 1 - The core viewpoint of the article is the release of measures by the National Healthcare Security Administration and the National Health Commission to support the high-quality development of innovative drugs, which includes increasing support for R&D and facilitating the inclusion of innovative drugs in basic medical insurance and commercial health insurance directories [1] - The continuous introduction of supportive policies is expected to improve the payment side for innovative drugs, leading to increased usage of these drugs by the public, thus benefiting the development of innovative pharmaceuticals [1] - The logic of recommending innovative drugs is shifting from solely focusing on international markets to also considering improvements in domestic payment systems, which could enhance the attractiveness of domestic innovative drugs [1] Group 2 - The Guotai Innovative Drug ETF (517110) tracks the SHS Innovative Drug (RMB) Index (931409), which is compiled by China Securities Index Co., Ltd. This index selects listed companies involved in the R&D, production, and sales of innovative drugs from the Shanghai, Hong Kong, and Shenzhen markets, focusing on companies with innovative capabilities in the pharmaceutical and biotechnology sectors [1]